The heterozygous Trp 53 null allele C57BL/6 (N5) mouse is susceptible to the rapid development of neoplasia by mutagenic carcinogens relative to control strains. This mouse model of chemical carcinogenesis demonstrates 1) dose-related rapid induction of tumors (26 wks), 2) multiple sites of carcinogen-specifi c tissue susceptibility, and 3) carcinogen-induced loss of heterozygosity involving the Trp53 wild-type allele or a p53 haploinsufficiency permitting mutation of other critical protooncogenes and/or inactivation of tumor suppressor genes driving tumorigenesis. Demonstration of mutation or loss ofheterozygosity involving the Trp53 locus is consistent with a common finding in human cancers and supports extrapolation between rodents and humans. Using diverse experimental protocols, almost all mutagenic rodent carcinogens (including all mutagens that are carcinogenic to humans), but not nonmutagenic rodent carcinogens, induce tumors within 26 weeks of continuous exposure. These characteristics and results indicate that the mouse heterozygous for the Trp53 null allele may be of significant use for the prospective identification of mutagenic carcinogens of potential risk to human health.
el-Deiry WS (1998). Regulation of p53 downstream genes. Semin Cancer Biol8(5): 345—357.
2.
Prives C., Hall PA ( 1999). The p53 pathway. J Pathol187(1): 112—126.
3.
Donehower LA, Harvey M., Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS, Bradley A. (1992). Mice defi cient for p53 are developmentally normal but susceptible to sponetaneous tumors. Nature356(6366): 215—221.
4.
Harvey M., McArthur MJ,Montgomery CAJ, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-defi cient mice. Nat Genet5(3): 225—229.
5.
Haseman JK, Elwell MR (1996). Evaluation of false positive and false negative outcomes in NTP long-term rodent carcinogenicity studies. Risk Anal16(6): 813—820.
6.
Karstadt M., Haseman JK (1997). Effect of discounting certain tumor types/sites on evaluations of carcinogenicity in laboratory animals. Am J Ind Med31(5): 485—494.
7.
Greenblatt MS, Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res54(18): 4855—4878.
8.
Hollstein M. , Sidransky D., Vogelstein B., Harris CC (1991). p53 mutations in human cancers. Science253(5015): 49—53.
9.
Weinberg RA (1991). Tumor suppressor genes. Science254(5035): 1138—1146.
10.
Knudson, AG JrHethcote HW, Brown BW (1975). Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA72(12): 5116—5120.
11.
Knudson AG (1996). Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol122(3): 135—140.
12.
Venkatachalam S., Shi YP, Jones SN, Vogel H., Bradley A., Pinkel D., Donehower LA (1998). Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. Embo J17(16): 4657—4667.
13.
French JE, Lacks GD, Trempus C., Dunnick JK, Mahler J., Tice RR, Tennant RW (2001). Loss of heterozygosity frequency at the Trp53 locus in p53 heterozygous ( + / - ) mice is carcinogen and tissue dependent . Carcinogenesis21(1): 101—108.
14.
Tennant RW, French JE, Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect103(10): 942—950.
15.
Tennant RW, Spalding J., French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res365:119—127.
16.
Kemp CJ, Donehower LA, Bradley A., Balmain A. (1993). Reduction of p53 gene dosage does not increase intitiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell74(5): 813—822.
17.
Kemp CJ, WheldonT, Balmain A (1994). p53-defi cient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Gen8: 66—69.
18.
Eastin WC, Haseman JK, Mahler JF, Bucher JR (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens . Toxicol Pathol26(4): 461—473.
19.
Ohyama K., Chung CH, Chen E., Gibson CW, Misof K., Fratzl P., Shapiro IM (1997). p53 infl uences mice skeletal development. J Craniofac Gen Dev Biol17(4): 161—171.
20.
Armstrong JF , Kaufman MH, Harrison DJ, Clarke AR (1995). Highfrequency developmental abnormalities in p53-deficient mice. Curr Biol5(8): 931—936.
21.
Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. (1995). A subset of p53-defi cient embryos exhibit exencephaly . Nat Gen10(2): 175—180.
22.
Silver LM (1995). Mouse genetics: Concepts and applications. New York: Oxford University Press. p 362.
23.
Hulla J., French J., Dunnick J. (2001). Chromosome 11 allelotypes refl ect mechanism of chemical carcinogenesis in heterozygous p53-deficient mice. Carcinogenesis21(1): 109—117.
24.
Hulla JE, French JE, Dunnick JK (2001). Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicol Sci60(2): 264—270.
25.
Bult CJ, Krupke DM, Sundberg JP, Eppig JT (2000). Mouse tumor biology database (MTB): Enhancements and current status. NucleicAcidsRes28(1): 112—114.
26.
Harvey M., McArthur MJ, Montgomery CAJ, Bradley A., Donehower LA (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J7(10): 938—943.
27.
Donehower LA , Harvey M., Vogel H., McArthur MJ, Montgomery CJ, Park SH, Thompson T., Ford RJ, Bradley A. (1995). Effects of genetic background on tumorigenesis in p53-defi cient mice. Mol Carcinog14(1): 16—22.
28.
Tennant RW, Stasiewicz S., Mennear J., French JE, Spalding JW (1999). Genetically altered mouse models for identifying carcinogens. IARC Sci Publ (146): 123—150.
29.
Spalding JW , French JE, Stasiewicz S., Furedi-Machacek M., Conner F., Tice RR, Tennant RW (2000). Responses of transgenic mouse lines p53( + / - ) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci53(2): 213—223.
30.
Mahler JF, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W. (1998). Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol26(4): 501—511.
31.
Mahler JF (2000). The use of genetically altered animals in toxicology . Toxicol Pathol28(3): 447—449.
32.
Tennant RW (1993). Stratification of rodent carcinogenicity bioassay results to refl ect relative human hazard. Mutat Res286(1): 111—118.
33.
Donehower LA (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol7(5): 269—278.
34.
Donehower LA , Godley LA, Aldaz CM, Pyle R., Shi YP, Pinkel D., Gray J., Bradley A., Medina D., Varmus HE (1996). The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model . Prog Clin Biol Res395:1—11.
35.
Venkatachalam S., Donehower LA (1998). Murinetumorsuppressormodels . Mutat Res400(1—2): 391—407.
36.
Stoll RE, Holden HE, Barthel CH, Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53 + / - transgenic mouse model [comment] [see comments]. Toxicol Pathol27(5): 513—518.
